The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition

Molecular point-of-care (mPOC) diagnostic solutions offer enhanced sensitivity and specificity compared to existing near-patient and rapid tests. They expand diagnostic capabilities in critical care units, physician offices, outpatient clinics, and community health posts, aiming to assess conditions or admit patients accurately. The concept blends the accessibility of point-of-care (POC) testing with the precision of molecular technology. The publisher has been covering mPOC on a regular basis since 2013.

Our latest report, The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition, is a valuable resource for understanding the size and growth potential of the molecular POC market from 2023-2028. mPOC has transitioned from a novel trend to a significant contributor to the market. Instruments from companies like Abbott, BioMérieux, Cepheid, and others play a substantial role in the IVD point-of-care market. Understanding these markets is crucial for assessing the opportunity in point-of-care testing and microbiology IVD.

The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings.

This reports provide real-world analysis and modeling for relevant circumstances. Analysts offer insights into near-patient molecular testing using small instruments.

The data in The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition includes information on systems, competitor analysis, and the size and growth of the market.

• What are the mPOC market opportunities beyond COVID-19?
• What are the current systems on the market?  Who’s winning?
• What’s the size of the Molecular Point-of-Care Market: 2023-2028
• Geographic Breakout of the Molecular Point-of-Care Market, 2023 (N. America, Europe, APAC, RoW)
• Segment Breakout of Molecular Point-of-Care Market, 2023 (Respiratory vs. Other)
• Near Patient Molecular IVD Market: 2023-2028
• Near Patient Molecular Market Share by Vendor, 2023
• Company Profiles

Competitive Analysis

Companies covered in this report, in profiles and/or product tables and market developments discussion include:

• Abbott Laboratories
• Aidian Oy
• Akonni Biosystems
• Anitoa
• binx health, inc.
• Biocartis NV
• BioGX
• bioMérieux SA
• Cepheid
• Credo Bioscience
• Cue Health
• Curetis NV
• Curiosity Diagnostics (Bio-Rad)
• DiaSorin S.p.A
• Domus Diagnostics
• Fluxergy
• GenMark Diagnostics
• Genomadix
• Greiner Bio-One GmbH
• LEX Diagnostics
• Meridian Bioscience, Inc.
• Mesa Biotech, Inc.
• MicroGEM
• Minute Molecular
• Nanopath
• QIAGEN NV
• QuantuMDx Group
• Quidel Corporation
• Roche
• Rover Diagnostics
• Sekisui Diagnostics LLC
• T2 Biosystems

Scope and Methodology

The market definition for molecular point-of-care can be challenging compared to other markets that the publisher covers as there are competing ideas about point-of-care or near-patient tests. But the future promise of molecular point-of-care is in sample-to-answer workflows and short result times that would make systems useful for a physician lab office. Therefore, systems like Roche’s cobas Liat, Abbott’s ID NOW (formerly the Alere i), and bioMérieux’s Biofire FilmArray 2.0 are the type of systems principally considered in market scope.

For the purposes of this report, systems must be capable of running CLIA-waived tests or have that capability in the near future. That being said there are a wide variety of molecular systems that could be classified as near-patient or rapid. Since sales of these systems may affect core markets, the publisher also includes in the discussion and in some additional market considerations rapid molecular testing that may be challenging to define as point-of-care but have a point-of-care-like quality such as HAI or STI testing.